$82.82
1.58% yesterday
NYSE, Nov 05, 10:00 pm CET
ISIN
US28176E1082
Symbol
EW

Edwards Lifesciences Stock price

$82.84
+6.28 8.20% 1M
+7.73 10.29% 6M
+8.81 11.90% YTD
+16.15 24.22% 1Y
+14.07 20.46% 3Y
+5.29 6.82% 5Y
+56.40 213.29% 10Y
+79.35 2,272.48% 20Y
NYSE, Closing price Wed, Nov 05 2025
-1.31 1.56%

New AI Insights on Edwards Lifesciences Insights AI Insights on Edwards Lifesciences

How does the company make money?
Who are the company’s main competitors?

Key metrics

Basic
Market capitalization
$48.6b
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
35.6 | 32.1
P/S
8.3 | 7.9
EV/Sales
- | -
EV/FCF
-
P/B
-
Financial Health
Equity Ratio
76.6%
Return on Equity
41.8%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$5.9b | $6.2b
EBITDA
- | $1.8b
EBIT
$1.6b | $1.7b
Net Income
$1.4b | -
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
4.7% | 13.2%
EBITDA
- | 12.3%
EBIT
4.7% | 13.0%
Net Income
-67.1% | -
Free Cash Flow
-
Margin (TTM | estimate)
Gross
78.2%
EBITDA
- | 29.8%
EBIT
27.7%
Net
23.3% | -
Free Cash Flow
-
More
EPS
$2.3
FCF per Share
-
Short interest
1.5%
Employees
16k
Rev per Employee
$340.0k
Show more

Is Edwards Lifesciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

Edwards Lifesciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

43 Analysts have issued a Edwards Lifesciences forecast:

28x Buy
65%
15x Hold
35%

Analyst Opinions

43 Analysts have issued a Edwards Lifesciences forecast:

Buy
65%
Hold
35%

Financial data from Edwards Lifesciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
5,884 5,884
5% 5%
100%
- Direct Costs 1,283 1,283
7% 7%
22%
4,600 4,600
4% 4%
78%
- Selling and Administrative Expenses 1,974 1,974
11% 11%
34%
- Research and Development Expense 1,083 1,083
3% 3%
18%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 1,632 1,632
5% 5%
28%
Net Profit 1,368 1,368
67% 67%
23%

In millions USD.

Don't miss a Thing! We will send you all news about Edwards Lifesciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Edwards Lifesciences Stock News

Neutral
Seeking Alpha
6 days ago
Edwards Lifesciences Corporation ( EW ) Q3 2025 Earnings Call October 30, 2025 5:00 PM EDT Company Participants Mark Wilterding - Vice President of Investor Relations Bernard Zovighian - CEO & Director Scott Ullem - Corporate VP & CFO Daniel Lippis - Corporate Vice President of JAPAC (Japan, Greater China & Asia Pacific) Daveen Chopra - Corporate Vice President of Transcatheter Mitral & Tricusp...
Positive
Reuters
6 days ago
Edwards Lifesciences beat Wall Street estimates for third-quarter results on Thursday, driven by strong demand for its artificial heart valves and other medical devices, with shares rising about 3% in extended trading.
Neutral
Reuters
6 days ago
Edwards Lifesciences said on Thursday its Chief Financial Officer Scott Ullem will step down by mid-2026 and remain in an advisory role after a successor is named.
More Edwards Lifesciences News

Company Profile

Edwards Lifesciences Corp. engages in the patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into three areas: Transcatheter Heart Valves, Surgical Structural Heart and Critical Care. The Transcatheter Heart Valves portfolio includes technologies designed to treat heart valve disease using catheter-based approaches as opposed to open surgical techniques. Its portfolio includes technologies designed for nonsurgical replacement of heart valves. The Surgical Structural Heart portfolio includes tissue heart valves and heart valve repair products for the surgical replacement or repair of a patient's heart valve. The Critical Care portfolio products through hemodynamic monitoring system measures a patient's heart function and fluid status in surgical and intensive care settings. The company was founded by Miles Lowell Edwards in 1958 and is headquartered in Irvine, CA.

Head office United States
CEO Bernard Zovighian
Employees 15,800
Founded 1958
Website www.edwards.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today